AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Public markets are showing early signs of reopening, as Q4 2025 saw a 157% increase in IPO deal volume compared to Q4 2024.

Amgen is hoping to gain a slice of the obesity market with MariTide, which it claims has a differentiated profile to other ...

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

GSK touted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.

Novo Nordisk is positioning itself as a long‑term leader across multiple obesity segments rather than relying on a single ...

GlobalData’s clinical trials dashboard is powered by the Pharma Intelligence Center, which boasts a highly comprehensive source of Clinical Trials collated from numerous government, non-government ...

AbbVie's deal with RemeGen is the first to be announced during the 2026 J.P Morgan Healthcare Conference, with more deals ...

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.